Licence Provides Route for Centyrin Development

UK-based Isogenica, a leader in the design and construction of synthetic antibody libraries and in the use of in vitro polypeptide display systems, has announced a new licensing agreement granting US biopharmaceutical company Aro Biotherapeutics Company (Aro), use of its proprietary in vitro CIS Display technology for the discovery, development and commercialisation of therapeutic products derived from Centyrin libraries generated using this technology.

Centyrins form a protein drug platform designed to address unmet needs through targeted delivery of a variety of drug payloads to specific cells or tissues.

Under the terms of the agreement, Isogenica will receive an upfront fee and annual licence payments and if therapeutic products are advanced into development, entitlement to additional milestone payments. The company will also undertake Centyrin discovery services at its Saffron Walden site on targets nominated by Aro.

Adam Collier, Isogenica’s Director of Commercial Development commented: “Isogenica continues to attract leading-edge partners, giving them access to our novel CIS Display technology and supporting them in advancing their own discovery programmes. Aro is an exciting new company with a unique technology and we look forward to our partnership with them.”